If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 23 Similar Profiles
Melanoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Skin Medicine & Life Sciences
Survival Medicine & Life Sciences
Mutation Medicine & Life Sciences
Safety Medicine & Life Sciences
fotemustine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2019

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M. C., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation

CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients

Dalmasso, B., Pastorino, L., Ciccarese, G., Andreotti, V., Grillo, F., Mastracci, L., Spagnolo, F., Ballestrero, A., Queirolo, P., Bruno, W. & Ghiorzo, P., Jan 1 2018, (Accepted/In press) In : Journal of the American Academy of Dermatology.

Research output: Contribution to journalArticle

Cyclin-Dependent Kinase Inhibitor p16
Germ-Line Mutation
Melanoma
Survival
Genes

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations

William, B., Claudia, M., Bruna, D., Virginia, A., Lorenza, P., Francesco, C., Marina, G., Francesco, S., Alberto, B., Paola, Q., Federica, G., Luca, M. & Paola, G., Jan 1 2018, In : Oncotarget. 9, 5, p. 5691-5702 12 p.

Research output: Contribution to journalArticle

Melanoma
Mutation
Germ-Line Mutation
Carcinogenesis
Mutation Rate